필리핀 모유수유아의 면역 건강 바이오마커와 분변 미생물군
필리핀 모유수유 유아의 면역 건강 바이오마커 및 분변 미생물군: 전향적 관찰 연구
This will be a prospective observational study aiming to investigate immune health biomarkers and fecal microbiota in 48-60 Filipino breastfed infants from birth to 12 months of age. An optional follow-up period of approximately 2 years will follow.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This will be a prospective observational study in healthy term infants who are exclusively breastfed. Approximately 48-60 healthy breastfed infants aged ≥14 to ≤35 days at enrollment will be recruited and followed up until 12 month of age at 6 on-site visits: V1 (baseline), V3 (2 months), V5 (4 months), V6 (6 month), V7 (10months) and V8 (12 months).
The 12-month observational period will be followed by a 2year optional follow-up period for a total duration of the study of approximately 3 years.
The primary objective of this clinical study is to characterize early immune system development in breastfed Filipino infants by investigating infant blood markers of systemic immunity.
The secondary objectives will include the characterization of infant fecal markers of immune health and gut barrier function, infant blood and fecal microbiome, interactions between immune development and microbiome maturation, infant fecal metabolic profile and fecal pH, infant gastrointestinal (GI) tolerance, infant anthropometric measurements, infant complementary food intake as well as infant illness and infection.
연구 유형
연구 유형
등록 (실제)
등록
연락처 및 위치
연구 장소
-
-
Manila
-
Manila, Manila, 필리핀 제도, 1780
- Asian Hospital and Medical Center
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Approximately 60 healthy breastfed infants aged ≥14 to ≤35 days at enrollment. To ensure balanced sex representation of the study population, approximately 30 males and 30 females will be enrolled in the study.
설명
Inclusion Criteria:
-
Written informed consent is obtained from parent(s)/ legally authorized representative(s) (LAR(s)).
-
Parent(s)/ LAR(s) must be able to provide evidence of parental authority and identity.
-
Parents/ LARs must understand the informed consent and other study documents.
-
Infants whose parent(s)/ LAR (s) has consented to blood collection as per protocol.
-
Able to temporarily store stool samples in a household freezer.
-
Infants whose parent(s)/LAR(s) are willing and able to comply with scheduled visits, and the requirements of the study protocol.
-
Infants whose parent(s)/LAR(s) can be contacted directly by telephone throughout the study.
-
Infants must meet all the following inclusion criteria to be eligible for enrollment into the study:
- Healthy term infant (≥37 weeks of gestation)
- At enrollment visit, postnatal age ≥14 to ≤35 days (date of birth = day 0)
- Birth weight is appropriate for gestational age (i.e., ≥ 2500g and ≤ 4500g)
- Infant has exclusively received breastmilk from birth to enrollment, and parent intends to continue exclusive breastmilk feeding until infant age 6 months.
Exclusion Criteria:
-
A medical condition or history that could increase the risk associated with study participation or interfere with the interpretation of study results, including:
- Evidence of major congenital malformations (e.g., cleft palate, extremity malformation).
- Suspected or documented systemic or congenital infections (e.g., human immunodeficiency virus, cytomegalovirus, syphilis).
- Previous or ongoing severe medical or laboratory abnormality (acute or chronic) which, in the judgment of the investigator, would make the infant inappropriate for entry into the study. Of note, children who are normally healthy but at the time of enrolment suffering from acute illness in a minor condition which are common in childhood and do not require some of the exclusionary medication mentioned below can be enrolled.
-
Presently receiving or have received prior to enrolment any of the following: medication(s) or supplement(s) which are known or suspected to affect the following: fat digestion, absorption, and/or metabolism (e.g., pancreatic enzymes); stool microbiota and characteristics (e.g., oral, or systemic antibiotics, glycerin suppositories, bismuth-containing medications, docusate, Maltsupex, or lactulose); growth (e.g., insulin or growth hormone); gastric acid secretion.
-
Infants whose parent(s) has(ve) not reached legal age of majority (18 years old) upon enrollment.
-
Currently participating or having participated in any interventional clinical trials since birth.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: OTHER
- 시간 관점: PROSPECTIVE
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Markers of systemic immunity
기간: Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months and 12months
|
Descriptive statistics of plasma immune proteomics using mass cytometry or immunoassays, and vaccine-specific antibodies assessed by ELISA |
Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months and 12months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Fecal markers of immune health and gut barrier
기간: Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months, 10 months and 12 months
|
|
Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months, 10 months and 12 months
|
|
Infant fecal microbiome
기간: Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months, 10 months and 12months
|
Microbiota composition, diversity, community types, and abundance of bacteria taxa |
Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months, 10 months and 12months
|
|
Fecal metabolic profile and pH
기간: Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months, 10 months and 12 months
|
pH and fecal organic acids, such as lactate, propionate, butyrate, acetate, valerate and total fecal organic acids, in wet stool weight and per dry stool weight |
Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months, 10 months and 12 months
|
|
Plasma Metabolomics
기간: Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months, and 12 months
|
Untargeted Plasma metabolomics Analyses |
Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months, and 12 months
|
|
GI Tolerance
기간: Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months
|
|
Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months
|
|
Weight
기간: Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months
|
Measurement of weight in grams |
Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months
|
|
Length
기간: Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months
|
Measurement of length in cm |
Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months
|
|
Head circumference
기간: Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months
|
Measurement of head circumference in cm |
Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months
|
|
Z-scores and percentiles
기간: Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months.
|
Changes in weight-for-age, weight-for-length, length-for-age, BMI-for-age, and head-circumference-for-age z-scores and percentiles calculated according to WHO standards |
Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months.
|
|
Infant illness and infection
기간: Infant age 6 months
|
Descriptive data and overall score derived from the Pediatric Immune System Index Questionnaire completed by parents |
Infant age 6 months
|
|
Infant Complementary Food Intake
기간: Infant age 6-12months
|
Descriptive data from complementary food questionnaire and 3-day food record |
Infant age 6-12months
|
|
Long-term infant illness (during the optional follow-up)
기간: Infant age 12 months, 18 months, 24 months, 30 months, and 36 months
|
Descriptive data from the Infant Illness Questionnaire completed by parents |
Infant age 12 months, 18 months, 24 months, 30 months, and 36 months
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of Adverse Events
기간: From infant age ≥14 to ≤35 days to 12 months
|
Incidents of adverse events from time of ICF signing at baseline, age ≥14 to ≤35 days, through the last study visit at age 12 months |
From infant age ≥14 to ≤35 days to 12 months
|
|
Concomitant medications and treatments
기간: From infant age ≥14 to ≤35 days to 12 months
|
All concomitant medications / treatments (including type and duration) used to treat illnesses and other conditions will be recorded continuously from time of ICF signing at baseline, age ≥14 to ≤35 days, through the last study visit at age 12 months |
From infant age ≥14 to ≤35 days to 12 months
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Maria Rosario JK Capeding, MD, Asian Hospital and Medical Center, Philippines
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 2313INF
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .